MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 70,000 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer directly owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Da Silva Jorge Santos also recently made the following trade(s):

• On Monday, December 8th, Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00.

MoonLake Immunotherapeutics Trading Up 0.3%

MLTX traded up $0.04 during trading on Wednesday, reaching $14.59. 1,293,485 shares of the company’s stock were exchanged, compared to its average volume of 1,743,358. The company’s fifty day moving average price is $11.20 and its 200-day moving average price is $36.25. The firm has a market capitalization of $937.12 million, a PE ratio of -4.39 and a beta of 1.21. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period last year, the company posted ($0.56) earnings per share. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MLTX shares. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 6th. Needham & Company LLC decreased their price objective on shares of MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $10.00 target price (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday, September 29th. Guggenheim decreased their target price on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 30th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $7.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $30.25.

Institutional Trading of MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC bought a new stake in MoonLake Immunotherapeutics during the 3rd quarter worth approximately $6,922,000. Nuveen LLC acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth $26,308,000. Two Sigma Investments LP acquired a new position in shares of MoonLake Immunotherapeutics during the third quarter worth $3,257,000. Vestal Point Capital LP grew its stake in shares of MoonLake Immunotherapeutics by 175.0% in the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after purchasing an additional 350,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in MoonLake Immunotherapeutics by 436.8% in the second quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock valued at $19,974,000 after purchasing an additional 344,335 shares during the period. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.